The FDA will not approve the novel contrast agent, florbetapir -- widely touted as a breakthrough for early diagnosis of Alzheimer's disease -- until manufacturer Eli Lilly puts a training program in place, the company announced.
More
Monday, March 21, 2011
FDA Puts Early Alzheimer's Test on Hold
The FDA will not approve the novel contrast agent, florbetapir -- widely touted as a breakthrough for early diagnosis of Alzheimer's disease -- until manufacturer Eli Lilly puts a training program in place, the company announced.
More
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment